The 12 month study of 430 overweight men and women (BMI of 30-43 kg/m2), was designed to assess the effectiveness of Xenical in patients who are responsive to treatment. Patients who achieved 5 per cent (approximately 5kg) weight loss after 3 months and maintained this after a further 3 months of Xenical treatment, were followed for one year. During this time weight loss and other health improvements, such as reductions in blood pressure, were assessed. The results suggest that the efficacy of Xenical in a real-life clinical practice setting is even greater than that demonstrated previously in clinical trials:
Commenting on the results, lead study investigator Professor Hermann Toplak from the Karl-Franzens-Universität, Graz, Austria said “These results demonstrate the significant benefits of rapid and continuous weight loss with Xenical in a clinical practice setting. Patients who respond rapidly to treatment continue with treatment and achieve long-term success.”
Results also demonstrated significant health gains associated with weight loss with Xenical. Specifically, people treated with Xenical achieved improvements in:
The reductions in blood pressure are a key finding as the number of overweight people with hypertension is almost three times higher than the number of adults with a healthy weight. 3 Xenical is the only prescription weight-loss medication, which can be used in patients with hypertension or uncontrolled hypertension.4
Xenical’s mode of action is unique. Unlike appetite suppressants, which have a history of withdrawals because of safety concerns, Xenical does not act on the central nervous system. As a result of Xenical’s non-systemic mode of action, it has a safety and tolerability profile, which makes it appropriate for use in a wide range of people. This is particularly important within the area of overweight / obesity, where a significant number of people suffer from, or are at risk of cardiovascular disease.
References:
Notes to Editors:
Xenical is the only available weight loss medication that works locally in the gut to prevent dietary fat absorption by around 30 per cent and effectively promotes weight loss. It is an effective therapy that not only helps patients lose weight, but also helps them maintain their weight loss. Xenical is well tolerated and unlike appetite suppressants, it does not act on the brain. In clinical trials people taking Xenical in conjunction with a mildly reduced calorie diet have shown twice as much weight loss as diet alone. Since it was first marketed in 1998, there have been more than 11.5 million patient treatments with Xenical world-wide. Xenical is licensed for weight management in 149 countries around the world. For further information please go to: www.managingyourweight.com
About Xenical Weight Management Programmes
Roche has developed the Xenical weight management programme (WMPs) for healthcare professionals to use with their patients. The programme aims to help patients set and reach realistic weight goals while modifying their dietary intake and behaviour in the long-term. The programmes are individually tailored to help people achieve their weight loss goals, and maintain weight loss, through healthy eating, physical activity, behaviour modification and pharmacotherapy.
Roche provides free patient support programmes in around 50 countries worldwide to help support people taking Xenical. Recent data demonstrated that patients enrolled in Xenical WMPs can significantly improve the levels of weight loss achieved and can increase their overall satisfaction and compliance with treatment.7
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-orientated healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche’s innovative products and services address prevention, diagnosis and treatment of diseases, thus enhancing people’s well-being and quality of life.
For further information please contact:
Antonia Betts
Shire Health International
Mobile: +44 (0) 7976 44 11 80
Jo Varney
Shire Health International
Mobile: +44 (0) 7788 718429